Genmab (GMAB) updates Articles of Association in new Form 6-K filing

Rhea-AI Filing Summary

Genmab A/S, a Denmark-based biotechnology company, submitted a Form 6-K as a foreign private issuer to the U.S. Securities and Exchange Commission for November 2025. The filing primarily makes Genmab’s updated Articles of Association available to U.S. investors as an exhibit.

The report states that this Form 6-K is incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the updated governance document becomes part of those employee share incentive-related registrations. The filing is signed on behalf of the company by Executive Vice President & Chief Financial Officer Anthony Pagano.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
3.1			Articles of Association

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: NOVEMBER 19, 2025

FAQ

What did Genmab (GMAB) file in this Form 6-K?

Genmab A/S filed a Form 6-K as a foreign private issuer, mainly to furnish its updated Articles of Association as an exhibit for U.S. investors.

Which document is attached to Genmab (GMAB)’s November 2025 Form 6-K?

The filing includes one exhibit: Genmab’s Articles of Association, listed as Exhibit 3.1 in the exhibit index.

How does this Genmab (GMAB) Form 6-K affect existing S-8 registrations?

The Form 6-K is incorporated by reference into Genmab’s Form S-8 registration statements (File Nos. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876), making its content part of those employee share plan registrations.

Who signed Genmab (GMAB)’s November 2025 Form 6-K?

The report was signed on behalf of Genmab A/S by Anthony Pagano, Executive Vice President & Chief Financial Officer.

Does this Genmab (GMAB) Form 6-K contain financial results or earnings data?

No financial results or earnings data are presented; the filing focuses on furnishing the updated Articles of Association and tying them into existing S-8 registration statements.

What is the purpose of Genmab (GMAB) using Form 6-K here?

Form 6-K allows Genmab, as a foreign private issuer, to provide important company information—here, its Articles of Association—to U.S. markets and incorporate it into existing registration statements.